Clinical Trial Update: Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study [Phase 2, Phase 3]

View source ↗

Summary

A pilot Phase 2/3 clinical trial is evaluating obinutuzumab for membranous nephropathy with PLA2R antibody decreases, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy

Drugs mentioned

• Gazyva (Obinutuzumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Membranous Nephropathy - PLA2R Induced | Phase 2, Phase 3 | Status: RECRUITING